In particular, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists with proven cardiovascular and renal benefits are prioritized for patients with established ASCVD, HF, or CKD independent of baseline HbA1c or metformin use. Here, SLC5A2 is linked to hydrops fetalis.